August 04, 2012 at 03:50 AM EDT
The Week in Review: Tigermed, a Hangzhou CRO, Plans IPO
Tigermed Consulting, the clinical-stage CRO headquartered in Hangzhou, will stage an IPO on the ChiNext exchange, with pricing expected August 6; Covidien officially opened its China medical device R&D facility in Shanghai’s Caohejing Hi-Tech Park; Luqa Pharma of Hong Kong in-licensed China rights to a scar treatment from Stratpharma, a Swiss company; Kinex Pharma, a New York-state startup developing cancer drugs, received an investment from Dr. Manson Fok of Hong Kong; Barclays Bank raised its rating for the China healthcare space, moving to Positive on the sector; and Roche will hire an additional 1,000 people in China over the next year, as the company’s China revenues continue to climb. More details…. Stock Symbols: (NYSE: COV) (VX: ROG) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here